Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 361

1.

Factor V Leiden and the risk for venous thromboembolism in the adult Danish population.

Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG.

Ann Intern Med. 2004 Mar 2;140(5):330-7.

PMID:
14996674
2.

A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism.

Middeldorp S, Meinardi JR, Koopman MM, van Pampus EC, Hamulyák K, van Der Meer J, Prins MH, Büller HR.

Ann Intern Med. 2001 Sep 4;135(5):322-7.

PMID:
11529695
3.

Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.

Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, Arruda V, Hillarp A, Reny JL.

Thromb Haemost. 2001 Sep;86(3):809-16. Erratum in: Thromb Haemost 2001 Dec;86(6):1598.

PMID:
11583312
4.

Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?

Spannagl M, Heinemann LA, Schramm W.

Eur J Contracept Reprod Health Care. 2000 Jun;5(2):105-12.

PMID:
10943572
5.

Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation.

Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennekens CH.

Ann Intern Med. 1997 Apr 1;126(7):528-31.

PMID:
9092318
6.

Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect: a retrospective analysis.

Meinardi JR, Middeldorp S, de Kam PJ, Koopman MM, van Pampus EC, Hamulyák K, Prins MH, Büller HR, van der Meer J.

Blood Coagul Fibrinolysis. 2001 Dec;12(8):713-20.

PMID:
11734673
7.

Prevalence of factor V Leiden and prothrombin 20210 A variant in Bulgarian patients with pulmonary thromboembolism and deep venous thrombosis.

Boyanovsky B, Russeva M, Ganev V, Penev M, Baleva M.

Blood Coagul Fibrinolysis. 2001 Dec;12(8):639-42. Erratum in: Blood Coagul Fibrinolysis. 2002 Jan;13(1):75. Russev M [corrected to Russeva M].

PMID:
11734663
8.

Factor V leiden homozygosity, dyspnea, and reduced pulmonary function.

Juul K, Tybjaerg-Hansen A, Mortensen J, Lange P, Vestbo J, Nordestgaard BG.

Arch Intern Med. 2005 Sep 26;165(17):2032-6.

PMID:
16186475
9.
10.

A prospective study of venous thromboembolism in relation to factor V Leiden and related factors.

Folsom AR, Cushman M, Tsai MY, Aleksic N, Heckbert SR, Boland LL, Tsai AW, Yanez ND, Rosamond WD.

Blood. 2002 Apr 15;99(8):2720-5.

11.

The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism.

Eichinger S, Weltermann A, Mannhalter C, Minar E, Bialonczyk C, Hirschl M, Schönauer V, Lechner K, Kyrle PA.

Arch Intern Med. 2002 Nov 11;162(20):2357-60.

PMID:
12418950
12.

The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis.

Middeldorp S, Henkens CM, Koopman MM, van Pampus EC, Hamulyák K, van der Meer J, Prins MH, Büller HR.

Ann Intern Med. 1998 Jan 1;128(1):15-20.

PMID:
9424976
13.

Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study.

Simioni P, Tormene D, Prandoni P, Zerbinati P, Gavasso S, Cefalo P, Girolami A.

Blood. 2002 Mar 15;99(6):1938-42.

14.

Increased risk for fetal loss in carriers of the factor V Leiden mutation.

Meinardi JR, Middeldorp S, de Kam PJ, Koopman MM, van Pampus EC, Hamulyák K, Prins MH, Büller HR, van der Meer J.

Ann Intern Med. 1999 May 4;130(9):736-9.

PMID:
10357692
16.

Summaries for patients. Blood clots in people with factor V Leiden mutation.

[No authors listed]

Ann Intern Med. 2004 Mar 2;140(5):I50. No abstract available.

PMID:
14996692
17.

Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.

Libourel EJ, Bank I, Meinardi JR, Baljé -Volkers CP, Hamulyak K, Middeldorp S, Koopman MM, van Pampus EC, Prins MH, Büller HR, van der Meer J.

Haematologica. 2002 Oct;87(10):1068-73.

18.

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis.

Simioni P, Prandoni P, Lensing AW, Manfrin D, Tormene D, Gavasso S, Girolami B, Sardella C, Prins M, Girolami A.

Blood. 2000 Nov 15;96(10):3329-33.

19.

Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses.

Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG.

Blood. 2002 Jul 1;100(1):3-10.

20.

Interrelation of hyperhomocysteinemia and inherited risk factors for venous thromboembolism. Results from the E.D.I.TH. study: a hospital-based case-control study.

Oger E, Lacut K, Le Gal G, Couturaud F, Abalain JH, Mercier B, Mottier D; EDITH (Etude des Déterminants/Interaction de la THrombose veineuse) Collaborative Study Group.

Thromb Res. 2007;120(2):207-14. Epub 2006 Nov 28.

PMID:
17126889

Supplemental Content

Support Center